Journal Article

DZNE-2025-01103

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Methodological validation of Miro1 retention as a candidate Parkinson's disease biomarker.

Drwesh, L. ; Arena, G. ; Merk, D. J. ; Ferrante, D. ; Gorgogietas, V. ; Gasser, T.DZNE* ; Grünewald, A. ; May, P. ; Brockmann, K.DZNE* ; Krüger, R. ; Wüst, R. ; Gloeckner, C. J.DZNE* ; Fitzgerald, J. C.

2025
Springer Nature [London]

This record in other databases:    

Please use a persistent id in citations: doi:10.1038/s41531-025-01115-8

Abstract: Mitochondrial markers help stratify Parkinson's disease (PD) patients. We use high-throughput blotting to quantify Miro1, Mfn2, and VDAC levels in fibroblasts, blood cells, and iPSC-derived neurons. Miro1 is specifically retained in PD cells but degraded in healthy ones after mitochondrial depolarization. We correlate Miro1 retention scores with pathogenic mutations, genetic background, age, and clinical data. This scalable assay and quantifiable score for mitochondrial-PD support biomarker development and pharmacological screening.

---

Contributing Institute(s):

1. Parkinson Genetics (AG Gasser)
2. Functional Neuroproteomics and Translational Biomarkers in Neurodegenerative Diseases (AG Gloeckner)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)
2. 352 - Disease Mechanisms (POF4-352) (POF4-352)

Appears in the scientific report 2025

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---